SCHEDULE 13G: Knoll Capital Management Discloses 5.2% Stake in Elicio Therapeutics

Knoll Capital Management, Fred Knoll, and Gakasa Holdings, LLC have jointly disclosed a beneficial ownership of 5.2% in Elicio Therapeutics, Inc.'s common stock.

Summary

• Knoll Capital Management, LLC, Fred Knoll, and Gakasa Holdings, LLC have filed a Schedule 13G, indicating beneficial ownership of 630,915 shares of Elicio Therapeutics, Inc. Common Stock.
• This aggregate amount represents 5.2% of the outstanding class of Elicio Therapeutics, Inc. Common Stock.
• The reporting persons, including Knoll Capital Management, LLC (organized in Florida), Fred Knoll (citizen of United States), and Gakasa Holdings, LLC (organized in United States), share both voting and dispositive power over all 630,915 shares.
• The filing states that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by an investment firm is generally a neutral to slightly positive signal, indicating investor interest without implying operational changes or financial performance.

Positives

• The disclosure of a significant 5.2% stake by an investment entity like Knoll Capital Management can be interpreted as a vote of confidence in Elicio Therapeutics, Inc. by a notable investor.

Risks

• No specific company operational or financial risks are detailed in this ownership disclosure filing, as it pertains solely to beneficial ownership.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure of a significant passive investment stake in a publicly traded company, common across all industries, including the biotechnology sector where Elicio Therapeutics operates. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The disclosure informs existing and potential shareholders about a significant institutional investor's stake, which can influence market perception and trading activity.

Key Dates

Keywords

Elicio Therapeutics, Knoll Capital Management, Fred Knoll, Gakasa Holdings, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Biotechnology